Rubius Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Rubius Therapeutics's estimated annual revenue is currently $13.2M per year.
- Rubius Therapeutics received $100.0M in venture funding in March 2018.
- Rubius Therapeutics's estimated revenue per employee is $45,588
- Rubius Therapeutics's total funding is $445M.
- Rubius Therapeutics's current valuation is $792.6M. (January 2022)
- Rubius Therapeutics has 289 Employees.
- Rubius Therapeutics grew their employee count by -8% last year.
Rubius Therapeutics Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Rubius Therapeutics?
Rubius Therapeutics is a biopharmaceutical company pioneering a new era of cellular medicines. Our proprietary RED PLATFORM was designed to genetically engineer and culture Red Cell Therapeutics that are selective, potent and ready to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Our initial focus is to advance RCT product candidates for the treatment of rare diseases, cancer and autoimmune diseases by leveraging three distinct therapeutic modalities - cellular shielding, potent cell-cell interaction and tolerance induction. We plan to file our first Investigational New Drug application (IND) for RTX-134 in phenylketonuria during the first quarter of 2019. We are planning to file additional INDs in rare diseases, cancer and autoimmune diseases in 2019, 2020 and beyond. The company, a 2017 Fierce 15 award winner, was founded in 2013, is based in Cambridge, MA and is currently expanding across the all functions within the organization. Having completed our an initial public offering (Nasdaq: RUBY), we are well capitalized to execute our vision and strategy. For more information, please visit us at www.rubiustx.com or follow us on Twitter.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
Rubius Therapeutics News
By Josh Beckerman. Rubius Therapeutics Inc. shares were recently down 24% to $2.42 after multiple analysts lowered price targets on Monday.
Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics. The...
CAMBRIDGE, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company...
U.S. Food and Drug Administration (FDA) Clears Investigational New Drug Application for RTX-224, Rubius’ Third Oncology Candidate Clinical Results Expected by Year-End or First Quarter 2022 in Phase 1 Trials of Single-Agent RTX-240 in Advanced Solid Tumors and Relapsed/Refractory Acute Myeloid ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Rubius Therapeutics Funding